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Purpose or Objective: The prognosis of oesophageal cancer 
(OC) is poor, with overall 5-year survival approximately 15%. 
The presence of lymph node metastases (LNMs) is a major 
prognostic indicator and the ability to identify LNMs is 
important. Texture analysis of medical images enables 
additional information to be extracted from routine staging 
investigations and quantifies intra-tumoural characteristics 
via non-invasive methods. The aim of the study is to obtain 
preliminary data investigating the association of texture 
variables and LNMs. 
 
Material and Methods: A prospectively maintained database 
including clinical, radiological and pathological details of 
consecutive OC patients with biopsy proven adenocarcinoma 
in South East Wales from October 2010 to August 2013 was 
retrospectively analysed. All patients underwent PET/CT 
staging. Consecutive patients were grouped into those with 
and without LNMs on endoscopic ultrasound (EUS), considered 
the superior staging investigation for loco-regional 
assessment. Texture analysis of the primary tumour was 
carried out on the PET images using PET-STAT, software 
developed and written in the Matlab-based open source 
software CERR. The tumour was outlined with ATLAAS, a 
learning algorithm for optimised automatic segmentation 
developed at Cardiff University. Seventeen variables 
including SUVmax, metabolic tumour volume (MTV), total 
lesion glycolysis (TLG) and intensity variability (IV) were 
calculated. Table 1 details all variables calculated. Patients 
with primary tumour volume less than 5 ml and distant 
metastatic disease were excluded. Independent T-tests were 
used to identify promising texture variables for future study. 
A p-value <0.05 was considered significant. Primary outcome 
was LNMs on EUS. 
 
Results: Eighty-one patients underwent staging with PET/CT 
and EUS [male 67, median age 66 (range 42-82)]. Forty 
patients were staged as N0 on EUS, with 41 having evidence 
of regional lymph node metastases. Independent T-tests 
demonstrated significant differences between patients with 
and without LNMs for MTV [mean 38.45 v 21.71; t(56.03)=-
2.449, p=0.017], TLG [mean 328.72 v 208.66; t(74.721)=-
2.023, p=0.047], Coarseness [mean 0.010 v 0.013; 
t(79)=3.107, p=0.003], Entropy [mean 6.15 v 5.91; t(79)=-
2.075, p=0.041] and IV [mean 21.09 v 13.45; t(64.366)=-
2.458, p=0.017]. 
 
Conclusion: Preliminary results have shown a number of 
texture variables that have the potential to predict LNMs. 
On-going work at our institution is investigating the added 
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Purpose or Objective: Perioperative chemotherapy (pCT) 
and neoadjuvant chemoradiotherapy (nCRT) are well-
established therapies to improve survival for resectable non-
metastatic esophageal carcinoma. However, the optimal type 
of treatment for esophageal adenocarcinoma is currently 
under debate. Until now, limited evidence is available to 
determine whether pCT or nCRT is most beneficial with 
regard to toxicity, pathologic outcome and survival. 
Therefore, the aim of this study was to compare toxicity, 
pathologic outcome and survival after pCT versus nCRT and 
surgery in patients with esophageal adenocarcinoma. 
 
Material and Methods: Consecutive patients who underwent 
pCT or nCRT followed by esophagectomy for cancer between 
October 2006 and September 2015 in a single institution were 
analyzed. The pCT regimen consisted of intravenous 
administration of epirubicin, cisplatin and capecitabin, 
whereas nCRT consisted of paclitaxel and carboplatin with 
concurrent radiotherapy. Toxicity of grade 3 or higher was 
scored according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events. Data on surgical 
procedures, complications and follow-up were collected from 
a prospectively maintained database. Full propensity score-
matching was applied to generate matched sets of cases 
based on pretreatment covariates in order to create 
comparable groups. Univariable analysis was performed to 
determine differences between the two groups. Disease-free 
survival (DFS) and overall survival (OS) were assessed using 
the Kaplan-Meier method and log-rank test. 
 
Results: A total of 189 eligible patients were identified of 
whom 19 were discarded after propensity matching; 86 
underwent pCT and 84 received nCRT. During preoperative 
therapy, thromboembolic events occurred more frequently in 
the pCT group (18% vs. 0%, p<0.001), while leukopenia 
occurred more frequently in the nCRT group (25 vs. 11%, 
p=0.013). Complete resection with no tumor within 1 mm of 
the resection margins (R0) was achieved in 90% of patients in 
the pCT group, as opposed to 96% in the nCRT group 
(p=0.103). Pathologic tumor regression was more frequently 
observed in patients who underwent nCRT compared to pCT 
(p<0.001). There was no significant difference between the 
groups with regard to risk of surgical complications, length of 
hospital stay or in-hospital mortality. Both treatments 
resulted in comparable 3-year DFS (49% vs. 53% for pCT and 
nCRT, respectively, log-rank p=0.774) and OS rates (48% vs. 
51%, log-rank p=0.842) (Figure 1). 
 
 
Conclusion: Perioperative chemotherapy (MAGIC) and 
neoadjuvant chemoradiotherapy (CROSS) were associated 
with comparable toxicity and postoperative morbidity. 
Although neoadjuvant chemoradiotherapy was associated 
with improved tumor regression compared to perioperative 
chemotherapy, this finding did not translate into improved R0 
resection or 3-year survival rates. 
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